Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Advanced Unfavorable Hodgkin Lymphoma | NCIT_C68665 | [An advanced Hodgkin lymphoma with unfavorable prognosis.] |
| HAQ-DI Without VAS - Help: Errands and Chores | NCIT_C132617 | [Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Errands and chores.] |
| TSQM Version 1.4 - Medication to Prevent or Treat Condition | NCIT_C132618 | [Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your condition?] |
| TSQM Version 1.4 - Way Medication Relieves Symptoms | NCIT_C132619 | [Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the way the medication relieves your symptoms?] |
| Helped and Using It Sometimes | NCIT_C107640 | [A response that something has helped an individual and it is being used sometimes.] |
| Helped and Using It Always | NCIT_C107641 | [A response that something has helped an individual and it is being used always.] |
| Fluticasone Propionate | NCIT_C29061 | [The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.] |
| SPL Race Terminology | NCIT_C107675 | [Terminology used for representation of the race designation in the framework of the Structured Product Labeling documents.] |
| Fluvastatin Sodium | NCIT_C29062 | [The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic activity. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Through the inhibition of mevalonate synthesis, statins, like fluvastatin, have been shown to inhibit the production of dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) and the isoprenylation of the intracellular G-proteins Ras and Rho, which may result in antiangiogenic, apoptotic, and antimetastatic effects in susceptible tumor cell populations.] |
| Dicycloplatin | NCIT_C107676 | [A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks. This mechanism results in the induction of apoptosis and cell growth inhibition. Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.] |
| Fluvoxamine Maleate | NCIT_C29063 | [The maleate salt form of fluvoxamine, a 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and antibulimic activities. Fluvoxamine blocks serotonin reuptake by inhibiting the serotonin reuptake pump of the presynaptic neuronal membrane leading to an increase of serotonin levels within the synaptic cleft. This results in facilitated serotonergic transmission and decreased serotonin turnover leading to antidepressant and antiobsessive-compulsive effects.] |
| Cytochrome P450 1A2 | NCIT_C17673 | [Cytochrome P450 1A2 (515 aa, ~58 kDa) is encoded by the human CYP1A2 gene. This protein is involved in the hydroxylation of fatty acids, steroids and xenobiotics.] |
| AAV-DC-CTL Tumor Cell Targeting Therapy | NCIT_C107677 | [A tumor-targeted therapy consisting of cytotoxic T lymphocytes (CTLs) that are exposed ex vivo to dendritic cells (DCs) transfected with a recombinant adeno-associated virus (rAAV) encoding a specific tumor associated antigen (TAA) gene. Autologous peripheral blood mononuclear cells (PBMC) are collected and separated into monocytes and lymphocytes. The monocytes are infected with the rAAV that carries the TAA gene; this is followed by co-culture of the monocyte-derived, mature rAAV-transfected DCs and the isolated lymphocytes to generate CTLs against the specific TAA. These CTLs are transfused back into the patient for cancer therapy. The CTLs specifically kill tumor cells expressing the TAA, which results in a reduction of tumor cell proliferation.] |
| Jaw Device | NCIT_C54020 | [A device designed to use opposing parts to close on and hold an object.] |
| Rovalpituzumab Tesirine | NCIT_C107678 | [An antibody-drug conjugate (ADC) containing a humanized IgG1 monoclonal antibody (MAb) directed against the delta-like protein 3 (DLL3), conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a maleimide-containing linker with an eight-carbon polyethylene glycol spacer and a cathepsin B-cleavable valine-alanine dipeptide, with potential antineoplastic activity. The MAb moiety of rovalpituzumab tesirine selectively binds to DLL3 on tumor cell surfaces. Upon internalization of the ADC, the dipeptide linker is cleaved and D6.5 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.] |
| Knife Device | NCIT_C54021 | [A cutting device usually consisting of a sharpened blade attached to a handle.] |
| FrSh61 (MEA) VHL33 Peptide | NCIT_C29065 | [A peptide derived from the tumor suppressor protein Von Hippel-Lindau (VHL). This peptide, sequence: MEAGRPRPCCAR, was constructed based on a frameshift mutation of one of the VHL gene products; the more abundant protein VHLp18(MEA) (where MEA stands for three amino acids, Met-Glu-Ala). Vaccination with FrSh61(MEA)VHL33 peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.] |
| Von Hippel-Lindau Peptide Vaccine | NCIT_C2492 | [A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein. (NCI04)] |
| Liposomal Rhenium Re 186 | NCIT_C107679 | [A therapeutic preparation consisting of the beta-emitting radioisotope rhenium Re 186 encapsulated in a nanoliposome, with potential antineoplastic activity. Upon intratumoral infusion of liposomal rhenium Re 186, the radioisotope releases radiation, which directly kills the tumor cells. The nanoliposomes facilitate the retention of the radioisotope by the tumor cells and localize the radiocytotoxicity to the tumor while sparing surrounding normal, healthy cells. Re-186 has a short half-life and a short path length, which contributes further to limiting the radiotoxicity to the tumor cells.] |
| Latch Device | NCIT_C54022 | [A fastening device for a swinging part usually consisting of a bar that is retained in a slot.] |